The protocol for the administration of the medicinal product Molnupiravir 200mg hard capsules, for the treatment of the disease, enters into force today in Cyprus COVID-19.
Below is the detailed information about the pill:
Drug information
Mechanism of Action and Effectiveness
It reduces the ability of the SARS-CoV-2 virus to multiply in the body by increasing the number of mutations in the genetic material of the virus (known as RNA), in a way that adversely affects the ability of the SARS-CoV-2 to multiply.
Reducing the risk of hospitalization or death in people with the disease COVID-19 who are at greater risk of serious illness.
To whom it is granted
Risk factors
How it is prescribed
How it is available
Important information
Reporting possible side effects
Through the national reporting system to the Pharmaceutical Services of the Ministry of Health with electronic submission to the link Yellow card or to the following contact details:
Pharmaceutical Services
Ministry of Health
CY-1475 Nicosia
Tel: + 357 22608607
Fax: + 357 22608669
website: www.moh.gov.cy/phs
High risk groups *
• Pre-existing Chronic Respiratory Disease (eg severe bronchial asthma, patient on chronic oxygen therapy or non-invasive ventilation [CPAP or BiPaP] at home, severe pulmonary hypertension (NYHA III and IV), severe pulmonary disease lobectomy).
• Severe Chronic Renal Failure (creatinine clearance below 15 ml / min and dialysis).
• Cardiac arrhythmia with permanent defibrillator or heart disease with permanent defibrillator and ventricular pacemaker.
• Heart failure of any etiology (ischemic or non-ischemic) stage according to NYHA III or IV.
• Cardiovascular disease:
• Recent acute coronary syndrome or revascularization surgery: angioplasty or stent implantation in the last 12 months,
Aorto-coronary bypass (CABG - bypass) in the last 12 months, and
• Recent SLE in the last 12 months or with established neurological semiology.
• Cardiomyopathies (History of documented myocarditis, hypertrophic, dilated, invasive (amyloidosis))
• Congenital heart disease after surgical correction with significant residual damage or non-corrected congenital heart disease with significant residual damage.
Active use of biological agents (eg TNF inhibitors, interleukin inhibitors) or other immunosuppressive drugs.
• Active chronic corticosteroids (≥20mg prednisone or its equivalent for ≥ 1 month)
• Patients with a history of solid organ or hematopoietic stem cell transplantation.
• Patients with solid or hematologic malignancy receiving chemotherapy or radiation or immunotherapy.
• HIV patients or patients with CD4 lymphocyte count <200 / mm3.
• Hereditary or acquired immunodeficiencies.
• Patients with Hemoglobinopathy falling into Category C - Patients at Very High Risk, according to the recommendations of the International Thalassemia Federation
In the context of the investigation of a case related to the burglary of an EAC substation in the province of Famagusta and...
The candidates of the municipal elections are expected to be thrown into the battle on the 9th of next June...
While we've all heard that we should take 10.000 steps a day, that number can…
As every year, this year the municipality of Paralimni organizes a rich program for...
As every year, this year the Municipality of Ayia Napa organizes a rich music and dance program...
The night of Holy Saturday in Limassol was eventful. Specifically, in one case in Ypsonas...